Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes alfatradiol (Pantostin/Ell Cranell) as a potential treatment. Users share opinions on its effectiveness in their regimen.

The conversation discusses hair regrowth strategies, including using dutasteride, minoxidil, finasteride, dermastamping, soy, curcumin, and possibly castor oil. Suggestions also include increasing dutasteride dosage, using oral minoxidil, topical finasteride, and tretinoin to enhance minoxidil efficacy.

A user reported full recovery from Post Finasteride Syndrome after 6 months of HCG treatment. They used 250IU of HCG three times a week.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

A user is using topical finasteride, keto shampoo, microneedling, and tretinoin for hair loss and is considering adding pyrilutamide. They notice some improvement at the temples and seek advice on whether to focus on cosmetic results despite daily shedding.

Topical Dutasteride 0.05% twice a week and Dutasteride Mesotherapy 0.01% once a week showed noticeable improvement in hair loss over six months without side effects. The user plans to add Minoxidil tablets 2.5mg daily to their treatment.

The user has tried various hair loss treatments, including minoxidil, finasteride, ketoconazole, biotin spray, oral medications, and a Revian cap, but has not seen lasting improvement. They are considering stopping treatments and are frustrated with the lack of progress and the financial and emotional toll.

The user is considering stopping topical minoxidil due to lack of improvement in hair growth and is exploring alternatives like oral minoxidil, topical finasteride, and tretinoin. They are hesitant about oral finasteride and dutasteride, and are open to trying oral minoxidil if available, despite concerns about potential heart-related side effects.

The conversation is about a user feeling hopeless due to hair loss despite using finasteride, dutasteride, and OM for over a year. Responses suggest therapy, self-improvement, and changing perspectives on appearance.

Tae147 has shared results of using pyrilutamide, a 5% concentration topical solution applied twice daily, in combination with minoxidil, to reduce scalp itchiness and hair shedding. Other users have shared their experiences with the treatment, as well as questions about its availability on the market.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

User noticed receding temples, used minoxidil and microneedling with positive results. Added saw palmetto and eucapil, experienced shedding and thinner hairline, but no side effects.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

The user has been using Dutasteride, Minoxidil, Ketoconazole, and RU58841 for hair loss but sees subpar results. Suggestions include adjusting treatments, considering a hair transplant, and addressing scalp inflammation.

The individual is struggling with hair loss and depression, having tried treatments like Finasteride, Dutasteride, and Minoxidil, but faced side effects and limited success. They are considering a hair transplant and other options while dealing with personal challenges, including knee injuries and weight issues, and are encouraged by others to focus on self-improvement and acceptance.

RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.

User tried various hair loss treatments with limited success. RU58841 was effective but caused side effects, now trying Eucapil and continuing Finasteride.

Low-level laser therapy (LLLT) is discussed as a supplementary treatment for hair loss, with users recommending brands like LaserCap, Ideatherapy, Capillus Pro, and iRestore Pro. Users suggest combining LLLT with treatments like minoxidil and finasteride for better results.

The user experiences severe side effects from finasteride and dutasteride, including low libido and anxiety, and is currently using oral minoxidil despite shortness of breath. They are seeking alternative treatments for hair loss, having tried pyrilutamide, fluridil, and RU58841 with no success, and are considering future treatments or a hair transplant.

Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.

The user has been using oral finasteride, topical minoxidil, and a dermaroller for hair regrowth, noticing most improvement between months 3 and 4. Other users commented on the positive results and shared their own treatment routines.

The user is treating diffuse thinning with finasteride, dutasteride, and oral minoxidil but hasn't seen significant improvement. Others suggest that results vary, with some maintaining hair and others considering transplants or future treatments.

The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.

PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.

The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.